BioCryst Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) saw unusually large options trading activity on Monday. Investors bought 2,675 call options on the stock. This is an increase of approximately 174% compared to the typical volume of 975 call options.

Analyst Ratings Changes

A number of research firms recently issued reports on BCRX. Royal Bank of Canada reiterated an "outperform" rating and set a $11.00 target price on shares of BioCryst Pharmaceuticals in a research report on Friday, April 11th. HC Wainwright reiterated a "buy" rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Needham & Company LLC reissued a "buy" rating and set a $15.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Thursday, April 10th. Cantor Fitzgerald began coverage on BioCryst Pharmaceuticals in a research report on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 target price for the company. Finally, Wedbush began coverage on BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $16.13.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX stock traded up $1.20 on Monday, hitting $10.13. The stock had a trading volume of 8,891,341 shares, compared to its average volume of 2,858,159. The business has a 50 day moving average of $7.69 and a 200 day moving average of $7.80. BioCryst Pharmaceuticals has a 12-month low of $4.75 and a 12-month high of $11.48. The stock has a market cap of $2.12 billion, a price-to-earnings ratio of -16.59 and a beta of 1.08.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The biotechnology company reported $0.20 EPS for the quarter, beating the consensus estimate of ($0.07) by $0.27. During the same quarter in the previous year, the business posted ($0.17) earnings per share. The business's revenue for the quarter was up 56.8% on a year-over-year basis. As a group, research analysts expect that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current fiscal year.

Institutional Trading of BioCryst Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Franklin Resources Inc. raised its stake in shares of BioCryst Pharmaceuticals by 177.8% during the 3rd quarter. Franklin Resources Inc. now owns 263,748 shares of the biotechnology company's stock worth $1,968,000 after purchasing an additional 168,790 shares during the period. KBC Group NV increased its holdings in BioCryst Pharmaceuticals by 80.1% during the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company's stock worth $77,000 after buying an additional 4,537 shares during the last quarter. R Squared Ltd bought a new stake in BioCryst Pharmaceuticals in the fourth quarter worth about $48,000. China Universal Asset Management Co. Ltd. grew its position in shares of BioCryst Pharmaceuticals by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 43,920 shares of the biotechnology company's stock valued at $330,000 after acquiring an additional 4,129 shares during the period. Finally, Choreo LLC purchased a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter worth approximately $106,000. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.